Drug
Repaglinide
Repaglinide: highest development phase Approved, developed by Aurobindo, Novo Nordisk. 2 trial records tracked on RxWires.
- Highest phase
- Approved
- Developer
- Aurobindo, Novo Nordisk
Trials
| Drug | Phase | Indication |
|---|---|---|
| REPAGLINIDE | Approved | |
| repaglinide NCT01562561 | Phase 3 | Diabetes |
Latest
No recent events.
Follow Repaglinide on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.